Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. BDMD
BDMD logo

BDMD Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
1.880
Open
1.815
VWAP
1.78
Vol
266.31K
Mkt Cap
68.31M
Low
1.720
Amount
474.98K
EV/EBITDA(TTM)
--
Total Shares
36.73M
EV
94.52M
EV/OCF(TTM)
--
P/S(TTM)
--
Baird Medical Investment Holdings Ltd is a holding company primarily engaged in the research and development, manufacture and sales of microwave ablation (MWA) medical devices. The Company’s MWA medical devices primarily include MWA needles and MWA therapeutic apparatus. The Company is also engaged in the sales of other medical devices, including catheters, ventilators, operation tables, medical gloves, syringes and other large medical machines and systems. The proprietary medical devices are used for treatment of benign and malignant tumors, including thyroid nodules, liver cancer, lung cancer and breast lumps. The Company primarily conducts its businesses in the domestic market.
Show More

Events Timeline

(ET)
2026-03-16
08:40:00
Baird Medical Successfully Holds Clinical Training Workshops in Indonesia
select
2026-01-26 (ET)
2026-01-26
08:50:00
Baird Medical Forms Strategic Partnership with Stonewood Key Capital
select
2026-01-07 (ET)
2026-01-07
08:40:00
Baird Medical Achieves Product Registrations in Pakistan and Vietnam
select
2025-12-17 (ET)
2025-12-17
08:40:00
Baird Medical Establishes Dedicated Manufacturing Base in the U.S.
select
2025-04-09 (ET)
2025-04-09
08:32:40
Baird Medical expands global presence of microwave ablation technology
select
2025-03-10 (ET)
2025-03-10
08:32:38
Baird Medical receives Indonesian approval for Microwave Ablation technology
select
2024-10-09 (ET)
2024-10-09
08:32:08
Baird Medical lists in U.S. on the Nasdaq Exchange
select

News

seekingalpha
9.5
04-29seekingalpha
Baird Medical Reports FY 2025 Financial Results
  • Financial Decline: Baird Medical reported a GAAP EPS of -$0.98 for FY 2025 with revenue of $22.5 million, a significant drop from $32.7 million in 2024, indicating major challenges in revenue generation and profitability.
  • Gross Margin Erosion: The gross profit for 2025 was $18.9 million, with a gross margin of 83.8%, down from 88.2% in 2024, reflecting increased pressure on cost control and market competitiveness.
  • Surge in Operating Expenses: Total operating expenses soared to $44.5 million in 2025 from $17.3 million in 2024, driven by higher selling, general and administrative, and R&D expenses, highlighting the company's ongoing investment in commercial expansion and product innovation.
  • Increased R&D Investment: R&D expenses rose significantly from $6.2 million in 2024 to $20.1 million in 2025, demonstrating the company's commitment to technological innovation and product development, despite the short-term financial strain.
PRnewswire
9.5
04-29PRnewswire
Baird Medical Reports 2025 Financial Results and Strategic Updates
  • Revenue Decline: Baird Medical reported a revenue of $22.5 million for 2025, a 39.2% decrease from $37 million in 2024, primarily due to policy-driven challenges in Mainland China that led to reduced sales volume and pricing pressure, highlighting significant market difficulties.
  • Executive Appointment: The company appointed Mark Saxton as CEO of Baird U.S. to spearhead commercial expansion in the U.S. market; with 25 years of experience in medical technology, Saxton is expected to drive new growth opportunities for the company.
  • Increased R&D Investment: Research and development expenses surged to $20.1 million in 2025 from $6.2 million in 2024, indicating the company's commitment to product innovation and market expansion, aimed at enhancing the competitiveness of its Microwave Ablation technology.
  • Widening Operating Loss: The operating loss for 2025 reached $25.6 million, significantly up from $15.3 million in 2024, reflecting the high operational costs and market pressures faced during the company's expansion efforts.
Newsfilter
9.5
04-29Newsfilter
Baird Medical Reports 2025 Financial Results and Strategic Updates
  • Revenue Decline: Baird Medical reported a revenue of $22.5 million for 2025, a 39.2% decrease from $37 million in 2024, primarily due to policy-driven market dynamics in Mainland China, necessitating an accelerated geographic expansion strategy to mitigate market challenges.
  • Executive Appointment: The appointment of Mark Saxton as CEO of Baird U.S. is expected to enhance commercial activities in the U.S. market, leveraging his 25 years of experience to drive market penetration and technology promotion in this critical region.
  • Increased R&D Investment: Research and development expenses surged to $20.1 million in 2025, a 225% increase from 2024, aimed at advancing microwave ablation technology and expanding market reach, underscoring the company's commitment to future growth.
  • Widening Operating Loss: The company reported an operating loss of $25.6 million in 2025, significantly higher than the $15.3 million loss in 2024, reflecting the dual pressures of rising operational costs and declining revenues, necessitating strategic measures to improve financial health.
PRnewswire
7.5
03-16PRnewswire
Baird Medical Successfully Hosts Clinical Training in Indonesia
  • Successful Clinical Training: Baird Medical executed two clinical training workshops in Indonesia, aimed at enhancing the skills of local healthcare providers, thereby improving patient care quality and reinforcing its leadership position in the Southeast Asian market.
  • Market Expansion Strategy: This training initiative is a key part of the company's strategic expansion into Southeast Asia, providing advanced knowledge of Microwave Ablation technology to help healthcare institutions improve treatment outcomes and meet the growing patient demand.
  • Technology Promotion: Through these workshops, Baird Medical showcased its expertise in minimally invasive technology to Indonesian healthcare providers, aiming to elevate industry standards through education and training, thus increasing market acceptance of its products.
  • Strengthening Regional Partnerships: The event not only fostered collaboration with Indonesian healthcare institutions but also laid the groundwork for future business expansion, demonstrating the company's commitment and long-term investment intentions in the Southeast Asian market.
Newsfilter
7.5
03-16Newsfilter
Baird Medical Successfully Conducts Clinical Training Workshops in Indonesia
  • Successful Clinical Training: Baird Medical executed two clinical training workshops in Indonesia at EKA Medika Hospital and RSCM Hospital, providing local physicians with hands-on experience in Microwave Ablation technology, thereby enhancing the company's influence in the Southeast Asian market.
  • Strategic Expansion: The workshops not only equipped regional healthcare providers with advanced tools and practical knowledge but also facilitated Baird Medical's strategic expansion in Southeast Asia, which is expected to improve patient care quality and drive business growth.
  • Market Leadership: As a market leader in minimally invasive diagnostics and treatment, Baird Medical's solutions are utilized in over 30 prestigious hospitals in the U.S., further solidifying its competitive advantage in the global medical device market.
  • Future Development Vision: Baird Medical is committed to fostering strategic collaborations with leading academic institutions to advance the research and development of surgical robotic systems and innovative minimally invasive surgical instruments, aiming to enhance patient outcomes through precision technology and demonstrate its foresight in medical innovation.
PRnewswire
8.5
03-12PRnewswire
Baird Medical Secures Regulatory Approval in Argentina
  • International Expansion Milestone: Baird Medical's regulatory clearance in Argentina marks a strategic advancement in its mission to promote Microwave Ablation technology globally, which is expected to significantly enhance the company's competitiveness in international markets.
  • Enhanced Certification Portfolio: The approval in Argentina enriches Baird Medical's international certification portfolio, which already includes the U.S. FDA, Indonesia, Malaysia, and Vietnam, thereby strengthening its foundation for global business expansion.
  • Regulatory Pipeline Advancement: The company is actively seeking formal registrations in key markets such as Egypt, Sri Lanka, the Philippines, and Pakistan, demonstrating its commitment to meeting the rising global healthcare demand.
  • Market Leadership Position: Baird Medical holds a leading position in the thyroid microwave ablation device market in China, and with its products gradually expanding into over 20 countries, it is poised to further solidify its leadership in the global medical device industry.

Valuation Metrics

The current forward P/E ratio for Baird Medical Investment Holdings Ltd (BDMD.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Baird Medical Investment Holdings Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

big gainers today
Intellectia · 137 candidates
Price Change Pct: >= $5.00List Exchange: XNYS, XNAS, XASE
Ticker
Name
Market Cap$
top bottom
PED logo
PED
PEDEVCO Corp
206.16M
BIAF logo
BIAF
bioAffinity Technologies Inc
4.81M
ISPC logo
ISPC
iSpecimen Inc
2.19M
AIFF logo
AIFF
Firefly Neuroscience Inc
24.73M
ELPW logo
ELPW
eLong Power Holding Ltd
407.04M
SVCO logo
SVCO
Silvaco Group Inc
101.11M
top gainers for today
Intellectia · 180 candidates
Price: >= $1.00Volume: >= 500,000Price Change Pct: >= $5.00List Exchange: XNYS, XNAS, XASE
Ticker
Name
Market Cap$
top bottom
UPXI logo
UPXI
Upexi Inc
54.77M
BDMD logo
BDMD
Baird Medical Investment Holdings Ltd
91.45M
BW logo
BW
Babcock & Wilcox Enterprises Inc
899.91M
INV logo
INV
Innventure Inc
220.11M
EOLS logo
EOLS
Evolus Inc
267.71M
SWIM logo
SWIM
Latham Group Inc
751.26M

Whales Holding BDMD

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Baird Medical Investment Holdings Ltd (BDMD) stock price today?

The current price of BDMD is 1.75 USD — it has decreased -5.91

What is Baird Medical Investment Holdings Ltd (BDMD)'s business?

Baird Medical Investment Holdings Ltd is a holding company primarily engaged in the research and development, manufacture and sales of microwave ablation (MWA) medical devices. The Company’s MWA medical devices primarily include MWA needles and MWA therapeutic apparatus. The Company is also engaged in the sales of other medical devices, including catheters, ventilators, operation tables, medical gloves, syringes and other large medical machines and systems. The proprietary medical devices are used for treatment of benign and malignant tumors, including thyroid nodules, liver cancer, lung cancer and breast lumps. The Company primarily conducts its businesses in the domestic market.

What is the price predicton of BDMD Stock?

Wall Street analysts forecast BDMD stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BDMD is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Baird Medical Investment Holdings Ltd (BDMD)'s revenue for the last quarter?

Baird Medical Investment Holdings Ltd revenue for the last quarter amounts to -1.02M USD, decreased -70.78

What is Baird Medical Investment Holdings Ltd (BDMD)'s earnings per share (EPS) for the last quarter?

Baird Medical Investment Holdings Ltd. EPS for the last quarter amounts to -780762.00 USD, decreased -43.51

How many employees does Baird Medical Investment Holdings Ltd (BDMD). have?

Baird Medical Investment Holdings Ltd (BDMD) has 146 emplpoyees as of May 09 2026.

What is Baird Medical Investment Holdings Ltd (BDMD) market cap?

Today BDMD has the market capitalization of 68.31M USD.